Accendra Health Inc
ACCH- Industry
- Wholesale-Medical, Dental & Hospital Equipment & Supplies
- SEC CIK
- 0000075252
In the last 90 days, Accendra Health Inc insiders filed 0 open-market purchases and 1 sale; no institution reported holding it in 13F filings for Q3 2026; no superinvestor holds it.
Other share classesACH
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:29 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $1.10B (39.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Feb 3, 2025 | Feb 20, 2024 | Feb 28, 2023 | Feb 23, 2022 |
| Revenue | $2.76B | $10.7B | $10.3B | $9.96B | $9.79B |
| Cost of revenue | $1.47B | $8.48B | $8.21B | $8.13B | $8.27B |
| Gross profit | – | $2.22B | $2.13B | $1.83B | $1.51B |
| Research and development | – | $13.0M | $13.2M | – | – |
| Selling, general and administrative | $1.07B | $1.91B | $1.81B | $1.63B | $1.12B |
| Operating income | $27.5M | -$207.8M | $104.5M | $142.9M | $368.5M |
| Interest expense | $107.2M | $143.8M | $157.9M | $128.9M | $48.1M |
| Income tax | $729.0K | $5.33M | -$13.4M | -$11.5M | $55.2M |
| Net income | -$1.10B | -$362.7M | -$41.3M | $22.4M | $221.6M |
| EPS, basic | $-14.31 | $-4.73 | $-0.54 | $0.30 | $3.05 |
| EPS, diluted | $-14.31 | $-4.73 | $-0.54 | $0.29 | $2.94 |
| Weighted shares, basic | 76.9M | 76.7M | 75.8M | 74.5M | 72.7M |
| Weighted shares, diluted | 76.9M | 76.7M | 75.8M | 76.2M | 75.5M |
| Margins and growth | |||||
| Gross margin | – | 20.7% | 20.6% | 18.3% | 15.5% |
| Operating margin | 1.0% | -1.9% | 1.0% | 1.4% | 3.8% |
| Net margin | -39.8% | -3.4% | -0.4% | 0.2% | 2.3% |
| Revenue growth, year over year | −74.2% | +3.6% | +3.8% | +1.7% | +15.4% |
| Net income growth, year over year | – | – | −284.5% | −89.9% | +641.8% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Feb 3, 2025 | Feb 20, 2024 | Feb 28, 2023 | Feb 23, 2022 |
| Cash and equivalents | $282.0M | $49.4M | $243.0M | $69.5M | $55.7M |
| Inventory | $74.4M | $1.13B | $1.11B | $1.33B | $1.50B |
| Total current assets | $547.9M | $2.02B | $2.10B | $2.30B | $2.32B |
| Property, plant and equipment | $256.2M | – | – | – | – |
| Goodwill | $1.23B | $1.33B | $1.64B | $1.64B | $390.2M |
| Intangible assets | $136.5M | $298.7M | $361.8M | $445.0M | $209.7M |
| Total assets | $2.45B | $4.66B | $5.09B | $5.39B | $3.54B |
| Accounts payable | $363.6M | $1.25B | $1.17B | $1.15B | $1.00B |
| Short-term debt | $250.0M | $45.5M | $206.9M | – | – |
| Total current liabilities | $947.1M | $1.87B | $1.89B | $1.57B | $1.34B |
| Total liabilities | $2.91B | $4.09B | $4.17B | $4.44B | $2.60B |
| Shareholders' equity | -$461.0M | $565.2M | $924.2M | $945.6M | $938.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Feb 3, 2025 | Feb 20, 2024 | Feb 28, 2023 | Feb 23, 2022 |
| Operating cash flow | – | $161.5M | $740.7M | $325.0M | $124.2M |
| Capital expenditures | $191.0M | $210.9M | $190.9M | $158.1M | $41.0M |
| Free cash flow | – | -$49.4M | $549.8M | $166.9M | $83.2M |
| Depreciation and amortization | $214.5M | $264.8M | $287.4M | $228.7M | $90.6M |
| Stock-based compensation | $12.9M | $26.8M | $23.2M | $21.0M | $25.0M |
| Dividends paid | – | – | $0 | $0 | $731.0K |
| Share buybacks | $10.2M | – | – | – | – |
| Investing cash flow | $144.4M | -$116.5M | -$137.3M | -$1.80B | -$53.6M |
| Financing cash flow | $188.1M | -$267.6M | -$417.3M | $1.50B | -$129.5M |
| Net change in cash | $232.6M | -$223.5M | $186.7M | $14.2M | -$62.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 0.5% | 0.3% | 0.2% | 0.2% | 0.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Sep 30, 2026 | 76.9M | −0.5% | SEC |
| Jun 30, 2026 | 76.9M | −0.4% | SEC |
| Mar 31, 2026 | 76.6M | 0.0% | SEC |
| Jan 31, 2026 | 76.4M | −1.0% | SEC |
| Oct 24, 2025 | 77.3M | +0.3% | SEC |
| Jul 31, 2025 | 77.2M | +0.2% | SEC |
| Apr 30, 2025 | 76.6M | +0.2% | SEC |
| Jan 31, 2025 | 77.2M | +0.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.